Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Vaccine|June 26, 2019
Use of controlled human infection models (CHIMs) to support vaccine development: US regulatory considerationsRoshan Ramanathan, Scott Stibitz, Douglas Pratt, et al.
Vaccine|August 2, 2017
Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virusSixun Yang, Doran Fink, Andrea Hulse, et al.
Pediatrics|August 25, 2018
Understanding FDA-Approved Labeling and CDC Recommendations for Use of VaccinesH Cody Meissner, Karen Farizo, Douglas Pratt, et al.
Biology Letters|December 18, 2008
Convergent evolution of 'creepers' in the Hawaiian honeycreeper radiationDawn M Reding, Jeffrey T Foster, Helen F James, et al.
The Journal of Infectious Diseases|March 15, 2014
Clinical evaluation of pertussis vaccines: US Food and Drug Administration regulatory considerationsKaren M Farizo, Drusilla L Burns, Theresa M Finn, et al.
JAMA|October 14, 2004
Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccineRobert P Wise, John Iskander, R Douglas Pratt, et al.
JAMA|December 8, 2005
Adverse events reported following live, cold-adapted, intranasal influenza vaccineHector S Izurieta, Penina Haber, Robert P Wise, et al.
The Journal of Infectious Diseases|February 27, 2020
Relative Effectiveness of Influenza Vaccines Among the United States Elderly, 2018-2019Hector S Izurieta, Yoganand Chillarige, Jeffrey Kelman, et al.
The Journal of Infectious Diseases|December 22, 2017
Clinical Development Strategies and Considerations for Zika Vaccine LicensureMarion F Gruber, Karen M Farizo, R Douglas Pratt, et al.
Pharmacoepidemiology and Drug Safety|June 7, 2019
Zostavax vaccine effectiveness among US elderly using real-world evidence: Addressing unmeasured confounders by using multiple imputation after linking beneficiary surveys with Medicare claimsHector S Izurieta, Xiyuan Wu, Yun Lu, et al.
Pageof 2